Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period

2021 ◽  
Author(s):  
Luis Gerardo Rodríguez‐Lobato ◽  
Arturo Pereira ◽  
Carlos Fernández de Larrea ◽  
Maria Teresa Cibeira ◽  
Natalia Tovar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Single Institution ◽  
Real World Data ◽  
World Data

P-124: The history of survival improvement in patients with Multiple Myeloma through real-world data in a 45-year period at a single institution

2021 ◽  
Vol 21 ◽  
pp. S102
Author(s):  
Luis Gerardo Rodríguez-Lobato ◽  
Arturo Pereira ◽  
C Fernández De Larrea ◽  
MT Cibeira ◽  
Natalia Tovar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Single Institution ◽  
Real World Data ◽  
World Data ◽  
History Of

Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients

2020 ◽  
Vol 20 (10) ◽  
pp. 704-711
Author(s):  
Stergios Intzes ◽  
Marianthi Symeonidou ◽  
Konstantinos Zagoridis ◽  
Zoe Bezirgiannidou ◽  
Aikaterini Pentidou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Socioeconomic Status ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Real World ◽  
Independent Prognostic Factor ◽  
Real World Data ◽  
World Data

scholarly journals Ideal Vial Size for Bortezomib: Real-World Data on Waste and Cost Reduction in Treatment of Multiple Myeloma in Brazil

2011 ◽  
Vol 14 (5) ◽  
pp. S82-S84 ◽  
Author(s):  
Luciana Clark ◽  
Ana Paula Castro ◽  
Anna Flávia Fortes ◽  
Fábio Santos ◽  
Otávio Clark ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Cost Reduction ◽  
Real World Data ◽  
World Data

scholarly journals PS1415 SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970–2015: REAL-WORLD DATA FROM A SINGLE CENTER

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 650-651
Author(s):  
L.G. Rodríguez-Lobato ◽  
A. Pereira ◽  
C. Fernández de Larrea ◽  
N. Tovar ◽  
M.T. Cibeira ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Single Center ◽  
Real World Data ◽  
World Data

scholarly journals Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico

Cancer ◽  
2018 ◽  
Vol 124 (9) ◽  
pp. 1946-1953 ◽  
Author(s):  
Luz Tarín-Arzaga ◽  
Daniela Arredondo-Campos ◽  
Victor Martínez-Pacheco ◽  
Odra Martínez-González ◽  
Alba Ramírez-López ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Practice ◽  
Real World ◽  
Novel Agents ◽  
Current Clinical Practice ◽  
Real World Data ◽  
World Data

scholarly journals Utilizing HealthTree ® Cure Hub's Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 Pandemic

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 5026-5026
Author(s):  
Nathan W. Sweeney ◽  
Jennifer M. Ahlstrom
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Real World ◽  
Online Survey ◽  
Stem Cell Transplant ◽  
Oral Treatment ◽  
Cell Transplant ◽  
Real World Data ◽  
World Data ◽  
Treatment Management

Abstract Background: Patients with multiple myeloma (MM) are uniquely susceptible to viral and bacterial illnesses, including COVID-19, due to their immunocompromised state, age, treatments, and comorbidities. With the advent of COVID-19, changes to treatment were recommended whenever possible, in order to reduce visits to the clinic. The total effect of these changes on cancer patients with multiple myeloma remains unclear. The aim of this project was to assess treatment management by changes to treatment of patients with MM during the COVID-19 pandemic. Methods: We utilized HealthTree ® Cure Hub for Multiple Myeloma (healthree.org) and invited patients with active MM cancer or precursor conditions to participate in an online survey. We analyzed patient responses to questions regarding their myeloma treatments during the COVID-19 pandemic. Results: 978 MM patients participated in the survey between February to June 2021. Since March 2020, 151 patients (15%) either delayed, postponed, or stopped a myeloma treatment because of COVID-19. The four most common treatments were daratumumab (20%), lenalidomide (15%), stem cell transplant (13%) and zoledronic acid (11%). There were 110 patients that canceled a planned myeloma treatment. Of these patients, 55 (50%) canceled a planned chemotherapy, 15 (14%) canceled a stem cell transplant, 1 (1%) canceled radiation and 39 (35%) indicated other. Eight patients replaced an intravenous or subcutaneous treatment with an oral treatment because of COVID-19. There were 9 patients that started a new myeloma treatment because of COVID-19, the most common being daratumumab (44%), ixazomib (22%), lenalidomide (22%) and carfilzomib (11%). Finally, 15 patients had their lenalidomide (50%), steroid (42%) and carfilzomib (8%) dose changed. Conclusions: Our results show that decision-making regarding treatment changes were made on an individual basis and that patients who required a change in treatment were the minority. Aggregating real-world data can provide evidence that despite the changes, patients with MM still received and efficacious treatment and avoided putting these patients at risk or mortality. Disclosures Ahlstrom: Bristol Myers Squibb: Other: Patient Advisory; Janssen: Other: Patient Advisory; Pfizer: Other: Patient Advisory; Takeda: Other: Patient Advisory.

Sign in / Sign up

Export Citation Format

Share Document